Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Stock Price Up 5.7%
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) rose 5.7% during trading on Monday . The company traded as high as $2.97 and last traded at $2.96. Approximately 161,850 shares were traded during trading, a decline of 80% from the average daily volume of 804,095 shares. The stock had previously closed at $2.80.
NAVB has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective (up previously from $6.00) on shares of Navidea Biopharmaceuticals in a research note on Monday, August 17th. Zacks Investment Research downgraded shares of Navidea Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 21st. Finally, Maxim Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Navidea Biopharmaceuticals in a research note on Friday, August 14th.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.01. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.60 million.
About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Featured Article: What does a bar chart mean for investors?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.